All In Biotech

NDA 207648 · Fresenius Kabi USA

Smoflipid 20%

Fish Oil, Medium Chain Triglycerides, Olive Oil, Soybean Oil · Intravenous · Lipid Emulsion

Last checked: Nov 19, 2026Latest source record: Jul 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Jul 13, 2016

Approved uses

2

Original approval plus efficacy supplements

Registered trials

448

117 Phase 3, 14 recruiting

FAERS reports

874

665 serious, 105 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 15, 2025.

SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. ( 1 )

Mechanism: SMOFlipid provides a biologically utilizable source of calories and essential fatty acids. Fatty acids serve as an important substrate for energy production. The most common mechanism of action for energy production derived from fatty acid metabolism is beta oxidation. Fatty acids are also important for membrane structure and function, as precursors for bioactive molecules (such as prostaglandins), and as regulators of gene expression.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 22, 2022 Supplement 5 · Efficacy · priority review LabelLetter
  • Jul 13, 2016 Original approval · Type 4 - New Combination LabelReviewLetter
4 products under this application
  • SMOFLIPID 20% · FISH OIL 3GM/100ML; MEDIUM CHAIN TRIGLYCERIDES 6GM/100ML; OLIVE OIL 5GM/100ML; SOYBEAN OIL 6GM/100ML (1000ML) · EMULSION, INTRAVENOUS · Prescription
  • SMOFLIPID 20% · FISH OIL 3GM/100ML; MEDIUM CHAIN TRIGLYCERIDES 6GM/100ML; OLIVE OIL 5GM/100ML; SOYBEAN OIL 6GM/100ML (250ML) · EMULSION, INTRAVENOUS · Prescription
  • SMOFLIPID 20% · FISH OIL 3GM/100ML; MEDIUM CHAIN TRIGLYCERIDES 6GM/100ML; OLIVE OIL 5GM/100ML; SOYBEAN OIL 6GM/100ML (500ML) · EMULSION, INTRAVENOUS · Prescription
  • SMOFLIPID 20% · FISH OIL 3GM/100ML; MEDIUM CHAIN TRIGLYCERIDES 6GM/100ML; OLIVE OIL 5GM/100ML; SOYBEAN OIL 6GM/100ML (100ML) · EMULSION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fish Oil" as an intervention, any sponsor and status, largest first.

All 448 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia58
  • vomiting53
  • off label use52
  • nausea51
  • malaise41
  • dyspnoea38
  • death36
  • intentional product use issue34
  • chills31
  • fatty acid deficiency31
  • hypertriglyceridaemia31
  • diarrhoea29

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20122
201410
20158
201634
201778
2018121
201998
202064
202168
202260
202391
202493
202575
202671

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,036 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.